OVERALL ABSTRACT The use of antiretroviral therapy to turn HIV infection into a chronic disease has been a major medical advancement. However, along with this has been the recognition of sequelae of HIV as a chronic condition, with end-organ consequences such as the HIV-associated neurocognitive disorder (HAND), as the brain is a target of HIV, and interactions with disease associated with aging. Indeed, the face of HIV infection is changing to an older population, and soon over half of infected individuals in the U.S. will be 50 years of age or greater. As age is the largest risk factor for neurodegenerative diseases, this graying of the HIV pandemic is a critical focus of study especially for the central nervous system. Furthermore, the brain can provide a reservoir for HIV, impacting efforts to find a functional cure. NIH P30 Centers support shared resources and facilities for research in a focused field. Here, we propose to build upon striking successes we have made in multiple areas to continue the UNMC Chronic HIV Infection and Aging in NeuroAIDS (CHAIN) Center. We have revised the Center based on our findings and current issues and needs in the field, and these closely follow the new NIH priority topics for using AIDS-designated funds, including neurological complications, comorbidies, cross-cutting basic research, long-acting therapeutics, and reservoir and cure. Through this Center mechanism, we will significantly facilitate research and accomplishments across these areas. Experts in a number of fields will direct Imaging, Therapeutics, Cell- Tissue-Animal, and Omics Cores. These, combined with a Developmental Core to stimulate new and innovative work and an Administrative Core to integrate and run the Center, will serve to significantly enhance our knowledge of neuroAIDS, its prevention and treatment, while joining others in work for an overall cure for HIV.
While HIV infected individuals are living longer due to treatment, effects on the central nervous system persist. Furthermore, as age is the highest risk factor for neurodegenerative diseases, knowledge of the effects of HIV and aging on the brain is critical. The brain can also provide a reservoir for the virus, hampering efforts towards a cure. Our Center will be a resource for investigators to diagnose, treat, prevent, and hopefully cure these consequences of HIV infection.
| McMillan, JoEllyn; Szlachetka, Adam; Slack, Lara et al. (2018) Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques. Antimicrob Agents Chemother 62: |
| Sillman, Brady; Woldstad, Christopher; Mcmillan, Joellyn et al. (2018) Neuropathogenesis of human immunodeficiency virus infection. Handb Clin Neurol 152:21-40 |
| Dave, Rajnish S; Jain, Pooja; Byrareddy, Siddappa N (2018) Functional Meningeal Lymphatics and Cerebrospinal Fluid Outflow. J Neuroimmune Pharmacol 13:123-125 |
| Dyavar, Shetty Ravi; Ye, Zhen; Byrareddy, Siddappa N et al. (2018) Normalization of cell associated antiretroviral drug concentrations with a novel RPP30 droplet digital PCR assay. Sci Rep 8:3626 |
| Ottemann, Brendan M; Helmink, Austin J; Zhang, Wenting et al. (2018) Bioimaging predictors of rilpivirine biodistribution and antiretroviral activities. Biomaterials 185:174-193 |
| Brenza, Timothy M; Schlichtmann, Benjamin W; Bhargavan, Biju et al. (2018) Biodegradable polyanhydride-based nanomedicines for blood to brain drug delivery. J Biomed Mater Res A 106:2881-2890 |
| Sathyanesan, Monica; Watt, Michael J; Haiar, Jacob M et al. (2018) Carbamoylated erythropoietin modulates cognitive outcomes of social defeat and differentially regulates gene expression in the dorsal and ventral hippocampus. Transl Psychiatry 8:113 |
| Zhou, Tian; Su, Hang; Dash, Prasanta et al. (2018) Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles. Biomaterials 151:53-65 |
| Thangaraj, Annadurai; Periyasamy, Palsamy; Liao, Ke et al. (2018) HIV-1 TAT-mediated microglial activation: role of mitochondrial dysfunction and defective mitophagy. Autophagy 14:1596-1619 |
| Kevadiya, Bhavesh D; Ottemann, Brendan M; Thomas, Midhun Ben et al. (2018) Neurotheranostics as personalized medicines. Adv Drug Deliv Rev : |
Showing the most recent 10 out of 374 publications
